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The first uterus transplantation was performed in 2000. As key milestones
are reached (long-lasting graft survival in 2011, and first birth from a
transplanted womb in 2014), the ethical debate around uterus transplant
evolves. We performed a systematic review of articles on uterus transplan-
tation. Ethical themes were extracted and categorized according to four
bioethical principles. Papers were divided into time periods separated by
key events in uterus transplant history: Phase I (first technical achievement,
2002–2011), Phase II (clinical achievement, 2012–2014), and Phase III
(after the first childbirth, 2015–2018). Eighty-one articles were included.
The majority of ethics papers were published in Phase III (65%,
P < 0.0001), that is after the first birth. Eighty percent of papers discussed
nonmaleficence making it the most discussed principle. The first birth
acted as a pivotal point: nonmaleficence was discussed by a lower propor-
tion of articles (P = 0.0073), as was beneficence (P = 0.0309). However,
discussion of justice increased to become the most discussed principle of
the time period (P = 0.0085). The ethical debate surrounding uterus trans-
plantation has evolved around landmark events that signify scientific pro-
gress. As safety and efficacy become evident, the focus of ethical debate
shifts from clinical equipoise to socioeconomic challenges and equitable
access to uterus transplantation.
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Introduction
The first human uterus transplantation (UTx) was per-
formed in 2000 in Saudi Arabia from a living donor [1].
The graft underwent two cycles of withdrawal bleeding so
was considered to be a technical achievement. However,
the graft ultimately failed secondary to avascular necrosis
three months later. The publication of this case sparked
ethical discourse. The next reported advance in human
uterus transplantation would not occur for another dec-
ade when a second uterus transplant was performed in
Turkey in 2011; this time with a deceased donor [2].
Results illustrated proof of concept, as the graft demon-
strated long-term survival and clinical pregnancy. How-
ever, true clinical success, defined as birth of viable
offspring, was not achieved [3]. Subsequently, a clinical trial




of uterus transplantation was performed in Sweden [4]
which culminated in the first human birth in 2014 [5].
Since its inception, uterus transplantation has
remained ethically controversial. The debate reflects the
complexity and experimental nature of UTx including
therapeutic misconception and its effect on informed
consent [6]; the implications of use of living versus
deceased donors [7,8]; and whether the risk–benefit
ratio is justified [9]. These issues were partially
addressed by the Montreal Criteria for ethical feasibility
[10,11]. This guideline was established in 2012 and
revised in 2013, when scientific success necessitated
research and clinical communities to consider the ethi-
cal ramifications of UTx. It set the international stan-
dard for the ethical execution of uterine transplantation
in humans. Later, UTx was encompassed under the
umbrella of vascularized composite allotransplantation
(VCAs) when the Organ Procurement and Transplant
Network (OPTN) established a new regulatory guideline
in the United States [12,13], which is used alongside the
Montreal criteria.
Uterus transplantation, similar to other life-enhancing
transplants, such as upper extremity and face, must
achieve more than technical achievement as defined by
mere allograft survival. Functional restoration (the abil-
ity to carry a pregnancy to term and give birth to a
viable child) is the primary goal, without which, the
clinical and scientific merit of UTx remains unestab-
lished [6,14]. Some consider it to be a restorative surgery
whose purpose is to treat infertility, and it is distinct
because of its life-giving potential [15]. However, the
potential benefits and risks to future offspring, donors
and recipients must be considered. Deceased donor
uteruses can be procured free from the physical risk
posed to living donors but have had reduced success in
achieving the primary goal [16]. The use of living
donors in UTx is often compared with the use of gesta-
tional surrogates as both employ another’s womb to
achieve parenthood and involves risks to third parties
[10,11]. Additionally, the recipient faces risk from
immunosuppression; although ephemeral, this risk is
combined with the need for multiple major surgeries
(transplantation, caesarean section and graft explanta-
tion) [16]. These risks must then be weighed against
potential benefits. Experience of childbearing and cre-
ation of a family are the primary motivations that drives
the push for UTx. Body integrity, or the sense of ‘feeling
whole’, can improve quality of life but is not considered
of sufficient benefit to justify the substantial risks
[10,11,14]. We must also consider challenges to informed
consent and patient autonomy, such as therapeutic
misconception. Therapeutic misconception occurs when
patients fail to understand the difference between
research and treatment which leads to unrealistic expecta-
tions [17]. Recipients must understand this to ensure
valid consent and nonexploitation.
Currently, no literature documents the evolution of
UTx ethics in response to scientific progress. It is
important for clinicians to be aware of the ethical con-
cerns surrounding this breakthrough treatment, and
how literature addressing these concerns have evolved.
Therefore, we performed a systematic review to evaluate
how the ethical discourse surrounding uterus transplan-




Following the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses guidelines, a literature
search of four databases (PubMed, Embase, Cochrane
and Scopus) was conducted from inception to 13 Octo-
ber 2018. The search strategy is available in
Appendix S1. A manual search of the bibliographies of
relevant papers was performed to identify additional
studies for possible inclusion. Inclusion criteria con-
sisted of articles that are (i) focused on human uterus
transplantation and the ethical concerns related to it
and (ii) written in the English language. Two indepen-
dent reviewers (LMN and SI) performed the initial liter-
ature search and screening of titles and abstracts. This
screened list of publications then underwent full article
review by two independent reviewers (LMN and SI).
Any disagreements regarding article inclusion were
resolved by discussion.
Thematic analysis
We framed this review in the context of the four bioethical
principles [18]: autonomy, beneficence, nonmaleficence
and justice. Ethical themes were extracted qualitatively by
two independent reviewers (LMN and SI) with the use of
NVIVO (NVivo qualitative data analysis Software; QSR
International Pty Ltd. Version 11, 2016, Melbourne, Aus-
tralia) as an organizational tool to enable better tracking of
thematic coding. Themes were then categorized according
to Beauchamp and Childress’ four principles: autonomy,
beneficence, nonmaleficence and justice. Definitions of
each of the four principles and how they relate to uterus
transplantation are included in Table 1.
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Temporal analysis
Medical advances are often provocative and ethical con-
cerns can change in response to landmark events. This dis-
course can help or hinder research and thus influence
future practice. Therefore, we analysed the change in ethics
over time by subdividing the papers into groups according
to key events in uterus transplantation: Phase I (following
the first technical achievement, 2002–2011); Phase II (after
proof of concept with the first clinical achievement, 2012–
2014); and Phase III (following the first human birth from
uterus transplantation, 2015–2018). Each subgroup begins
the year after a landmark event to take into consideration
the delay in time to publication.
Data analysis
Data were organized using Microsoft Excel (Microsoft
2016, Redmont, WA, USA) and analysed in SPSS (IBM
Corp 2016. Armonk, NY, USA). Chi-square and Fisher’s
exact tests were used to compare percentages and
proportions, as appropriate.
Records identified through 
primary database search 
(n = 241)
Records identified from 
secondary sources
(n = 43)
Records after duplicates removed
(n = 123)
Full text articles screened for 
eligibility
(n = 100)
Full text articles excluded
(n = 19)
• Language other than 
English (n = 4)
• Abstract only (n = 3)
• Did not include ethical 
themes (n = 11)
• Duplicate (n = 1)






















Figure 1 Flow chart demonstrating
screening and selection of articles in
literature search according to PRISMA
guidelines.
Table 1. Descriptions of Beauchamp and Childress’ four ethical principles and how each relates to uterus
transplantation
Description Relevance to UTx
Autonomy Acknowledge and respect a
patient’s right to choose free
from interference
Recipients and donor must give voluntary informed consent without
pressure from external influences; recipients must be made aware
that UTx does not automatically equate to childbirth (therapeutic
misconception)
Beneficence Always promoting good and
acting in the best interest of
the patient
UTx has the potential to treat infertility, thus improving quality of life;
donors can receive psychological benefit through altruism; the
resultant functional gain can give life to children
Nonmaleficence Primum non nocere – first, do
no harm. Either directly,
through adverse events or
absence of care
Recipients undergo a minimum of three surgeries (transplantation,
Caesarean section and hysterectomy) and immunosuppression;
donors are at risk of exploitation, in addition to physical and
psychological harm; embryos face risk from immunosuppression in
utero
Distributive justice Distributing potential benefits,
risks and costs fairly and
appropriately, treating all
patients in the same manner
UTx is an alternative in cases where adoption/surrogacy is infeasible;
criteria must be set to prioritize recipient for uterus allocation;
funding is not yet in place so may only be financially feasible for the
affluent
UTx, uterus transplantation.
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Results
We identified 284 citations. Following deduplication, we
reviewed 123 unique articles. Of these, 81 articles met
inclusion criteria and were included in the qualitative
analysis (Appendix S2 and S3). Figure 1 summarizes the
screening and article selection process.
Papers were published between 2002 and 2018. The
mean number of publications per year was 4.8 [range:
0–20] (Fig. 2). Of the four bioethical principles, non-
maleficence was the most common theme (64 articles;
79%), followed by justice (63 articles; 78%) and auton-
omy (55 articles; 68%), while beneficence (39 articles;
48%) was least common.
Subthemes
Each bioethical principle encompasses a range of dis-
tinct subthemes, each with its own implications for sur-
gical practice. Therefore, papers were further grouped
by the primary subthemes within each principle.
Within the 64 articles on nonmaleficence, risk to
living donor (surgical, psychological) (n = 39, 61%)
and the recipient (repeated surgeries, immunosuppres-
sion; n = 39, 61%) were the greatest concerns. This
was followed by concerns on the immunosuppressive
risk for the baby (n = 26, 41%) and lack of regulation
with risk of black market organ trade (n = 8, 13%;
Fig. 3a).
Justice appeared in 63 publications, and its relevant
subthemes included equity (equal opportunity for child-
birth including alternative reproductive methods;
n = 43, 68%), allocation of transplant (n = 29, 46%)
and funding of the procedure (n = 19, 30%; Fig. 3b).
Of the 55 papers featuring autonomy, they included
subthemes of therapeutic misconception (n = 45, 82%),
informed consent of the donor (n = 27, 49%) and self-
determination of the recipient and donor (right to
choose) (n = 12, 22%; Fig. 3c).
Thirty-nine publications discussed beneficence with a
primary focus on ‘feeling whole’ and improved quality
of life of the recipient (n = 27, 69%), reflecting the view
of UTx as a life-enhancing procedure. Subthemes of
functional restoration with childbirth (n = 22, 56%)
and the psychological benefit of donor altruism (n = 4,










2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Figure 2 The number of publications on the ethics of uterus transplantation per year in relation to notable uterus transplant milestones.
OPTN/UNOS, Organ Procurement and Transplantation Network/United Network for Organ Sharing; POD, postoperative day; UTx, uterus trans-
plantation.
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This data indicates that informed consent of recipient
and donors (autonomy), improving quality of life
(beneficence), mitigating risks to both recipients and
donors (nonmaleficence) and ensuring reproductive
equality (justice) are the most discussed ethical topics in
uterus transplantation.
Evolution of ethics
There was an increase in publications after each phase
with the majority of publications occurred after achieve-
ment of the primary goal with the first birth from a
transplanted uterus (65%). There was a significant
increase in articles published between Phase III and
Phases I (P < 0.0001), and II (P < 0.0001; Fig. 4), indica-
tive of increasing interest in the ethics of uterus trans-
plantation after achieving the primary goal of UTx.
Within Phases II and III, there was a statistical difference
between the proportions of at least two of the four
bioethical principles discussed (P = 0.0442 and
P < 0.0001, respectively; Table 2), signifying that the
bioethical principles are not discussed equally in the UTx
literature after the first clinical achievement in 2011.
When comparing the time periods after the first clin-
ical achievement and first birth from a transplanted
womb (Phases II versus III), we observed a significant
decrease in the percentage of papers discussing non-
maleficence (100% vs. 70%, P = 0.0073) and
beneficence (72% vs. 42%, P = 0.0309). In addition, the
proportion of papers discussing justice increased signifi-
cantly from the first technical achievement to the first
clinical achievement (Phase I: 40% vs. Phase II: 83%,
P = 0.0346) and after the first successful birth (Phase I:
40% vs. Phase III: 83%, P = 0.0085; Fig. 5). There was
no difference between the proportions of papers dis-
cussing autonomy over time.
We then analysed subthemes for temporal changes.
Within nonmaleficence, there was a notable decrease in
the occurrence of ‘immunosuppressive risk to newborn’
after the first birth from a transplanted womb (Phase I:
67% vs. Phase II: 22%, P = 0.0152). Conversely, there
was an increase in concerns for the ‘risks to living
donors’ at the same time point (Phase II: 39% vs. Phase
III: 70%, P = 0.0399; Fig. 6). No significant temporal
trends were noted in any subthemes within autonomy,
beneficence or justice.
Discussion
With 18 human births from transplanted uteruses to
date [19,20], uterus transplantation is quickly becoming
an established treatment alternative for women with
absolute uterine infertility concerns. Advancements have
been made at a rapid rate – progressing from the first
human UTx failed attempt to a successful human birth
in less than 15 years [1,5]. The ethical discourse has
Figure 3 The major ethical subthemes of (a) nonmaleficence, (b) justice, (c) autonomy and (d) beneficence, and their appearance in literature
from 2002 to 2018.
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responded to and evolved with increasing clinical expe-
rience and successes. Furthermore, the unequivocal suc-
cess of uterus transplant, demonstrated by the first
viable human birth in 2014, acts as a pivotal point.
The ethical prerequisite for non-life-saving trans-
plants relies on the prospect of either decreased morbid-
ity or superior outcomes, when compared with the
alternatives. Morbidity from uterine transplantation
includes effects of immunosuppression, and the risk of
surgery to both donor and recipient. Success of UTx is
determined by a clear endpoint: childbirth. We are in
strong support of uterus transplantation when ethical
benchmarks are met. Based on the results of our
study and previous ethical guidelines [10,11,21], we
summarized ethical considerations and recommenda-
tions for uterus transplantation (Table 3).
The progression of ethical discourse follows a pattern
seen in other VCA transplants [22,23]. The first stage
coincides with initial scientific attempts when we ask
‘what can we do?’ As advances occur, the question shifts
to ‘what should we do?’ This is demonstrated by the
increase in publications and the establishment of a regu-
latory ethics framework after the first clinical achievement
in 2011 [10]. This question gains more importance when
the procedure is not life-saving but life-enhancing, such
as face and upper extremity transplantation, which have,
and continue to face, similar ethical challenges as they
become more successful [24,25]. During these early
stages, the principle of nonmaleficence dominates, a
trend that is also reflected in the upper extremity and
face transplantation literature [22,23]. This may not be
surprising given the physician’s doctrine of ‘do no
harm’. Not only is there clinician hesitation to place
patients at risk through experimental therapies, but
there are also systematic procedures and checks to iden-
tify, mitigate and remove risk to patients. Ethics litera-
ture is centred on proving the procedure has low
enough risk relative to any potential benefit. This may
be reflected in our results; wherein beneficence is the
principle that is least discussed in the UTx literature.
Alternatively, in the case of UTx, where the beneficence
is more clearly apparent, it may be that the potential
benefits require less discussion.
There was also an emphasis on ensuring informed con-
sent from the recipient as evidenced by the prevalence of
the ‘therapeutic misconception’ subtheme. Classically,
therapeutic misconception is defined as ‘when individuals
do not understand that the defining purpose of clinical















Figure 4 The number of ethics publications according to time per-
iod.
Table 2. Proportion of papers within each time period that discussed autonomy, beneficence, nonmaleficence or justice
Autonomy (%) Beneficence (%) Nonmaleficence (%) Justice (%) P-value
Phase I (n = 10) 50 40 90 40 0.0749
Phase II (n = 18) 67 72 100 83 0.0442














Figure 5 The percentage of papers discussing autonomy, benefi-
cence, nonmaleficence and justice divided by time period.
*P = 0.0346, **P = 0.0309, ***P = 0.0073, ****P = 0.0085.
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of whether the subjects enrolled in the trial may poten-
tially benefit from the intervention’ [26]; and it is often
seen in discussion of experimental therapies. In the con-
text of UTx, it relates to patients’ unrealistic expectations
that may prevent true informed consent. Thus, the preva-
lence of this subtheme is consistent with the status of
UTx as an experimental therapy rather than the standard
of care. As the uncertainty of outcomes decreases with
each new birth, UTx will likely transition in status, mark-
ing another milestone.
The first successful human birth from a transplanted
womb in 2014 was a watershed moment for the ethical
discourse surrounding uterus transplantation. We see a
relative decrease in discourse around principles of non-
maleficence and beneficence whereas the discussion of
justice more than doubles to become the most prevalent
theme within the same time period. It is clear that as
the questions of safety and efficacy are answered, a new
question arises: how can we do this fairly? Concerns
about use of alternative fertility methods and ensuring
equity in reproduction dominated the discussion,
quickly followed by organ allocation and financial con-
cerns. This progression from ethical questioning to
addressing socioeconomic equity issues is mirrored in
other organ transplantations [22,23,27].
Uterus transplantation is seen as an alternative in cases
where surrogacy is illegal and a genetic connection to the
child is sought, thereby increasing a woman’s reproduc-
tive autonomy [28]. The recommendations emphasize
that experience of childbearing and creation of a family
should be the primary motivation. Interestingly, unlike
other life-enhancing transplantations, body integrity is
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**
Figure 6 The percentage of papers discussing each subtheme of the four bioethical principles: (a) autonomy, (b) beneficence, (c) nonmalefi-
cence and (d) justice, according to time period. *P = 0.0399, **P = 0.0152.




Recommendation to ensure ethical
conduction of uterus transplantation
Indication Experience of pregnancy and birth of
viable child
Candidate Physically healthy and able to withstand
immunosuppression
Passes psychological assessment
Possesses viable embryos available for
implantation
Understands the temporary nature of
uterus transplant
Donor Deceased donors: Loved ones must give
informed consent
Living donors: Understands risks of
hysterectomy and gives informed
consent
Offspring Foetal preterm and post-term
monitoring
266 Transplant International 2020; 33: 260–269
ª 2019 Steunstichting ESOT
Ngaage et al.
point of contention as the debate moves to inclusion of
transgender women [29]. Established recommendations
on how to prioritize recipients for this scarce resource
are necessary to ensure equitable distribution and access
to treatment [10,11]. The need to impose structure and
regulations in allocation is highlighted in the correspond-
ing increase in the appearance of the subtheme of black
market trade (nonmaleficence) in the literature. In prac-
tice, lack of regulation can become synonymous with
permission [29], and similar issues have been observed in
renal transplantations in which organs can be sourced
from living donors, in addition to the deceased [30].
Some countries have imposed strict bans, while others
have permitted commercial sale [31,32]. The debate on
organ transplant tourism is still ongoing [33,34]. This
may be further exacerbated by the uncertainty in funding
sources. Although the surgical procedure could be cov-
ered once the patient is approved for treatment, the abil-
ity to obtain a viable embryo is crucial in order to give
birth through UTx. Therefore, access to in vitro fertiliza-
tion (IVF) is often required to be eligible for UTx [21].
This may limit access to UTx to those who can afford
this additional procedure.
The impact of the first birth from UTx was also seen
within the subthemes, most notably for those within the
nonmaleficence principle. The overall downtrend in the
discussion of nonmaleficence may be attributed to the
‘risk to recipient’ and ‘immunosuppressive risk to the
newborn’ subthemes. In reconstructive transplantation,
potential harm to the recipient primarily relate to the
requirement of long-term immunosuppression that can
result in reduced life expectancy [35]. However, unlike
upper extremity and face transplantation, UTx is
intended to be temporary, in that the graft is removed
following childbirth, as the last of a series of major opera-
tions. As such, immunosuppression is not lifelong, which
adds a dimension that does not exist for other life-en-
hancing transplants. It would therefore be reasonable to
expect that over time, as more UTx recipients undergo
graft explantation following childbirth, concerns regard-
ing long-term toxicity of immunosuppression may fur-
ther decrease. To adequately prepare the patient prior to
transplantation, counselling should emphasize plans for
explantation after childbirth, as well as explantation in
the case of failure to conceive or deliver a viable child
with the graft. These discussions should be ongoing
throughout the course of treatment. At this time, no
evidence-based recommendations for the maximum
duration to retain a transplanted uterus have been estab-
lished. We believe that these decisions should be individ-
ualized, based on the patient’s clinical status, goals and
continuing discussion of risks and benefits between the
patient and transplant team.
Clinical evidence may also assuage ethical concerns
for immunosuppressive risk to the newborn. This is
illustrated by the decrease of this subtheme in the litera-
ture after the first viable birth. Additionally, there is
wealth of information from solid organ transplantation
demonstrating the safety of pregnancies in patients on
immunosuppression [36]. Approximately 14% of recipi-
ents of nonuterus, solid organ transplants are women in
their childbearing years, and pregnancy after transplan-
tation is becoming increasingly common [37]. Women
who become pregnant after solid organ transplant face
greater risks when pregnant compared with UTx recipi-
ents. They have often received immunosuppression for
significantly longer, have comorbidities and chronic dis-
ease, such as hypertension and diabetes, which add
additional risks to pregnancy, and are unable to stop
immunosuppression during pregnancy or risk losing the
transplanted organ. Strategies are in place to ensure safe
and successful birth in a post-transplant setting
(Table 4).
Strikingly, there was a notable increase in concerns for
living donors in the same time period as the downtrend
of the nonmaleficence theme. In contrast to other VCA
transplants, the UTx donor pool includes living donors.
In VCA transplants, such as face, penis and upper
extremity, donor grafts are limited to deceased donors.
To date, most births from UTx have resulted from living
uterus donation, and increased success results in
increased demand. Thus, there is increased interest in use
of living donors. The inclusion of living donors in UTx
means that donor ethics more closely resemble that of
other living solid organ transplants, such as kidney or
liver, than other VCA transplants. Living donor trans-
plantation is controversial because it exposes donors to
risks for the potential benefit of third parties (recipients)
[38]. The potential risks must be balanced with the
donor’s autonomy and right to choose. The risk of
Table 4. Strategies for successful pregnancy after solid
organ transplantation [37]
1. Accurate and early diagnosis and dating of pregnancy
2. Close monitoring of graft function and immunosuppres-
sive drug levels
3. Maternal surveillance for hypertension, gestational dia-
betes, pre-eclampsia and bacterial or viral infection
4. Foetal preterm surveillance for malformation, foetal
growth and well-being
5. Aim to deliver at term
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hysterectomy in this population is unknown, although
serious complications including reoperation have been
reported [39]. However, uteruses are sourced from
donors who no longer wish to childbear and, therefore,
have exhausted their function. Nevertheless, living dona-
tions are fraught with the potential for commercial sale of
organs [40–42]. This concern is highlighted by the
appearance of the subtheme of black market trade (non-
maleficence) in our results. In practice, lack of regulation
can become synonymous with permission [43], and simi-
lar issues have been observed in renal transplantations in
which organs can be sourced from living donors, in addi-
tion to the deceased [43]. Therefore, established recom-
mendations on how to prioritize recipients for this scarce
resource are necessary to ensure equitable distribution
and access to treatment. Recent births have occurred
from deceased donor uteruses [19,20], so it is also possi-
ble that this UTx subtheme will trend down in the future.
There are several limitations within this review.
Although an exhaustive literature search was conducted,
it is possible that relevant articles were excluded. In
addition, we did not include media and news articles.
Although the majority of publications explicitly named
at least one of the bioethical principles within the text,
several articles were less direct in stating the primary
bioethical principles of interest. Therefore, some inter-
pretation by the authors was required to identify the
primary themes. To minimize the procrustean nature of
this approach, subthemes were extracted first and after
discussion were arranged into the bioethical principles.
Additionally, two independent reviewers analysed each
article to reduce the effect of reviewer subjectivity.
Another limitation is the different group sizes of publi-
cations in all three phases, as well as the low number of
publications in the first era. Therefore, caution should
be taken when interpreting results.
We have highlighted the past and current discussion
on the ethics of uterus transplantation in the hope of
advancing the debate. The evolution of ethics in uterus
transplantation follows a pattern that has been previ-
ously seen in other life-enhancing transplants: initial
clinical hesitancy as we venture into the unknown, fol-
lowed by an emphasis on prevention of harm and
ensuring informed consent, and with increasing accep-
tance comes a focus on equitable access and socioeco-
nomic challenges. These changes are in response to
landmark events in UTx that signify scientific progress
in the area, and the first birth from a transplanted
womb, the measurement of true success in a uterus
transplant, acts as a pivotal point in the discussion.
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